Molecular dynamics of the full-length p53 monomer

Cell Cycle

Volumn 12, Issue 18, 2013, Pages 3098-3108

  Chillemi, Giovanni ^a   Davidovich, Pavel ^b   D'Abramo, Marco ^a   Mametnabiev, Tazhir ^b   Garabadzhiu, Alexander Vasilievich ^b   Desideri, Alessandro ^c   Melino, Gerry ^d,e  

^a CINECA   (Italy)

^b ST PETERSBURG STATE INSTITUTE OF TECHNOLOGY TECHNICAL UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cancer; Cell death; DNA damage; P53; P63; P73

Indexed keywords

MONOMER; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DNA BINDING; HYDROGEN BOND; MOLECULAR DYNAMICS; PROLINE RICH PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE; TRANSACTIVATION;

CANCER; CELL DEATH; DNA DAMAGE; P53; P63; P73;

DNA; HUMANS; HYDROGEN BONDING; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; STATIC ELECTRICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884831789     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26162     Document Type: Article

References (171)

1. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12:259-65; PMID:21427767; http://dx.doi.org/10.1038/nrm3086
2. Paskulin DD, Cunha-Filho JSL, Souza CAB, Bortolini MC, Hainaut P, Ashton-Prolla P. Tp53 PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure. Cell Death Dis 2012; 3:e392; PMID:23013791; http://dx.doi.org/10.1038/cddis. 2012.116
3. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on Tp53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC Tp53 database. Hum Mutat 2007; 28:622-9; PMID:17311302; http://dx.doi.org/10.1002/humu.20495
4. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ 2012; 19:180-3; PMID:22095277; http://dx.doi.org/10.1038/cdd.2011.148
5. Marcel V, Olivier M, Mollereau B, Hainaut P, Bourdon JC. First International p53 Isoforms Meeting: 'p53 isoforms through evolution: from identification to biological function'. Cell Death Differ 2011; 18:563-4; PMID:21151028; http://dx.doi.org/10.1038/cdd.2010.156
6. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008; 77:557-82; PMID:18410249; http://dx.doi.org/10.1146/ annurev.biochem.77.060806.091238
7. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145:571-83; PMID:21565614; http://dx.doi.org/10.1016/j.cell.2011.03.035
8. Soria C, Estermann FE, Espantman KC, O'Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 2010; 466:1076-81; PMID:20740008; http://dx.doi.org/10.1038/nature09307
9. Menendez D, Resnick MA, Haran TE. Transactivation by low and high levels of human p53 reveals new physical rules of engagement and novel super-transactivation sequences. Cell Cycle 2012; 11:4287-8; PMID:23095671; http://dx.doi.org/10.4161/cc.22467
10. Guseva NV, Rokhlin OW, Bair TB, Glover RB, Cohen MB. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget 2012; 3:183-94; PMID:22383394
11. da Costa NM, Hautefeuille A, Cros M-P, Melendez ME, Waters T, Swann P, Hainaut P, Pinto LF. Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle 2012; 11:4570-8; PMID:23165212; http://dx.doi.org/10.4161/cc.22843
12. Insinga A, Cicalese A, Faretta M, Gallo B, Albano L, Ronzoni S, Furia L, Viale A, Pelicci PG. DNA damage in stem cells activates p21, inhibits p53, and induces symmetric self-renewing divisions. Proc Natl Acad Sci U S A 2013; 110:3931-6; PMID:23417300; http://dx.doi.org/10.1073/pnas.1213394110
13. Eckner R. p53-dependent growth arrest and induction of p21: a critical role for PCAF-mediated histone acetylation. Cell Cycle 2012; 11:2591-2; PMID:22751433; http://dx.doi.org/10.4161/cc.21235
14. Quaas M, Müller GA, Engeland K. p53 can repress transcription of cell cycle genes through a p21(WAF1/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle 2012; 11:4661-72; PMID:23187802; http://dx.doi.org/10.4161/cc.22917
15. Kibe R, Zhang S, Guo D, Marrero L, Tsien F, Rodriguez P, Khan S, Zieske A, Huang J, Li W, et al. IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death Differ 2012; 19:1139-51; PMID:22281704; http://dx.doi.org/10.1038/cdd.2011.203
16. Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013; 110:E89-98; PMID:23236145; http://dx.doi.org/10.1073/pnas.1216922110
17. Boren J, Brindle KM. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ 2012; 19:1561-70; PMID:22460322; http://dx.doi.org/10.1038/cdd.2012.34
18. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C, et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 2012; 11:4436-46; PMID:23151455; http://dx.doi.org/10. 4161/cc.22778
19. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012; 148:244-58; PMID:22265415; http://dx.doi.org/10.1016/j.cell.2011.12.017
20. Ginestier C, Charafe-Jauffret E, Birnbaum D. p53 and cancer stem cells: the mevalonate connexion. Cell Cycle 2012; 11:2583-4; PMID:22751434; http://dx.doi.org/10.4161/cc.21092
21. Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493:542-6; PMID:23242140; http://dx.doi.org/10.1038/ nature11743
22. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013; 493:689-93; PMID:23334421; http://dx.doi.org/10.1038/nature11776
23. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 2010; 107:7461-6; PMID:20351271; http://dx.doi.org/10.1073/pnas.1002459107
24. Chang JY, Chiang MF, Lin SR, Lee MH, He H, Chou PY, Chen SJ, Chen YA, Yang LY, Lai FJ, et al. TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis 2012; 3:e302; PMID:22534828; http://dx.doi.org/10.1038/cddis.2012.36
25. Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis 2011; 2:e160; PMID:21593792; http://dx.doi.org/10.1038/cddis.2011.42
26. Wang Y, Zhou BP. FBW7-Aurora B-p53 feedback loop regulates mitosis and cell growth. Cell Cycle 2012; 11:4113-4; PMID:23099923; http://dx.doi.org/10. 4161/cc.22607
27. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19:1038-48; PMID:22193543; http://dx.doi.org/10.1038/cdd.2011.190
28. Leontieva OV, Blagosklonny MV. Hypoxia and gerosuppression: the mTOR saga continues. Cell Cycle 2012; 11:3926-31; PMID:22987149; http://dx.doi.org/10. 4161/cc.21908
29. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2:e164; PMID:21614094; http://dx.doi.org/10.1038/ cddis.2011.48
30. Gogna R, Madan E, Kuppusamy P, Pati U. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications. Cell Death Dis 2012; 3:e286; PMID:22419115; http://dx.doi.org/10.1038/cddis.2012.15
31. Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, Rotter V. Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol 1986; 6:3232-9; PMID:3023970
32. Conforti F, Yang AL, Agostini M, Rufini A, Tucci P, Nicklison-Chirou MV, et al. Relative expression of TAp73 and Delta Np73 isoforms. Aging-Us 2012; 4:202-5
33. Grespi F, Melino G. P73 and age-related diseases: is there any link with Parkinson Disease? Aging (Albany NY) 2012; 4:923-31; PMID:23271007
34. Tucci P. Caloric restriction: is mammalian life extension linked to p53? Aging (Albany NY) 2012; 4:525-34; PMID:22983298
35. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19:2122-37; PMID:16131611; http://dx.doi.org/10.1101/gad.1339905
36. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18:244-52; PMID:18406616; http://dx.doi.org/10. 1016/j.tcb.2008.03.003
37. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18:1487-99; PMID:21760596; http://dx.doi.org/10.1038/cdd.2011.81
38. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, Kivioja T, Ignatiev I, Kel A, Taipale J, et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19:1992-2002; PMID:22790872; http://dx.doi.org/10.1038/cdd.2012.89
39. Lee S, Kim JY, Kim YJ, Seok KO, Kim JH, Chang YJ, Kang HY, Park JH. Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal stresses. Cell Death Differ 2012; 19:1613-22; PMID:22522597; http://dx.doi.org/10.1038/cdd. 2012.40
40. Blagosklonny MV. Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells. Oncotarget 2012; 3:601-7; PMID:22802145
41. Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012; 3:228-35; PMID:22410433
42. Madapura HS, Salamon D, Wiman KG, Lain S, Klein G, Klein E, Nagy N. p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP. Cell Cycle 2012; 11:4563-9; PMID:23165210; http://dx.doi.org/10.4161/cc.22810
43. Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer? Oncotarget 2012; 3:1272-83; PMID:23174755
44. Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, et al. Non-cellautonomous tumor suppression by p53. Cell 2013; 153:449-60; PMID:23562644; http://dx.doi.org/10. 1016/j.cell.2013.03.020
45. Hock AK, Vousden KH. Tumor suppression by p53: fall of the triumvirate? Cell 2012; 149:1183-5; PMID:22682240; http://dx.doi.org/10.1016/j.cell.2012.05. 024
46. Berns A. Cancer: The blind spot of p53. Nature 2010; 468:519-20; PMID:21107421; http://dx.doi.org/10.1038/468519a
47. Rouaud P, Fiancette R, Vincent-Fabert C, Magnone V, Cogné M, Dubus P, Denizot Y. Mantle cell lymphoma- like lymphomas in c-myc-3'RR/p53+/- mice and c-myc-3'RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin. Oncotarget 2012; 3:586-93; PMID:22592113
48. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010; 468:572-5; PMID:21107428; http://dx.doi.org/10.1038/nature09535
49. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao X-H, Refetoff S, Montagna C, Di Cristofano A. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2:1109-26; PMID:22190384
50. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010; 468:567-71; PMID:21107427; http://dx.doi.org/10.1038/nature09526
51. Krimpenfort P, Song J-Y, Proost N, Zevenhoven J, Jonkers J, Berns A. Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 2012; 482:538-41; PMID:22358843; http://dx.doi.org/10.1038/ nature10790
52. Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, et al. CKIα ablation highlights a critical role for p53 in invasiveness control. Nature 2011; 470:409-13; PMID:21331045; http://dx.doi.org/10.1038/nature09673
53. Altilia S, Santoro A, Malagoli D, Lanzarini C, Ballesteros Álvarez JA, Galazzo G, Porter DC, Crocco P, Rose G, Passarino G, et al. Tp53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging (Albany NY) 2012; 4:28-39; PMID:22289634
54. Fortini P, Ferretti C, Pascucci B, Narciso L, Pajalunga D, Puggioni EMR, Castino R, Isidoro C, Crescenzi M, Dogliotti E. DNA damage response by singlestrand breaks in terminally differentiated muscle cells and the control of muscle integrity. Cell Death Differ 2012; 19:1741-9; PMID:22705848; http://dx.doi.org/10.1038/cdd.2012.53
55. Huang BH, Zhuo JL, Leung CHW, Lu GD, Liu JJ, Yap CT, Hooi SC. PRAP1 is a novel executor of p53-dependent mechanisms in cell survival after DNA damage. Cell Death Dis 2012; 3:e442; PMID:23235459; http://dx.doi.org/10.1038/cddis. 2012.180
56. Shandilya J, Wang Y, Roberts SGE. TFIIB dephosphorylation links transcription inhibition with the p53-dependent DNA damage response. Proc Natl Acad Sci U S A 2012; 109:18797-802; PMID:23115335; http://dx.doi.org/10.1073/ pnas.1207483109
57. Hill R, Madureira PA, Waisman DM, Lee PWK. DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget 2011; 2:1094-108; PMID:22190353
58. Seillier M, Peuget S, Gayet O, Gauthier C, N'Guessan P, Monte M, Carrier A, Iovanna JL, Dusetti NJ. Tp53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ 2012; 19:1525-35; PMID:22421968; http://dx.doi.org/10.1038/cdd.2012.30
59. Malek M, Guillaumot P, Huber AL, Lebeau J, Pétrilli V, Kfoury A, Mikaelian I, Renno T, Manié SN. LAMTOR1 depletion induces p53-dependent apoptosis via aberrant lysosomal activation. Cell Death Dis 2012; 3:e300; PMID:22513874; http://dx.doi.org/10.1038/cddis.2012.39
60. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A 2012; 109:18060-5; PMID:23077249; http://dx.doi.org/10.1073/pnas.1018858109
61. Pujals A, Renouf B, Robert A, Chelouah S, Hollville E, Wiels J. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis. Cell Death Dis 2011; 2:e184; PMID:21796156; http://dx.doi.org/10.1038/cddis.2011.67
62. Esposito F, Tornincasa M, Federico A, Chiappetta G, Pierantoni GM, Fusco A. High-mobility group A1 protein inhibits p53-mediated intrinsic apoptosis by interacting with Bcl-2 at mitochondria. Cell Death Dis 2012; 3:e383; PMID:22932725; http://dx.doi.org/10.1038/cddis.2012.126
63. Minutolo A, Grelli S, Marino-Merlo F, Cordero FM, Brandi A, Macchi B, Mastino A. D(-)lentiginosineinduced apoptosis involves the intrinsic pathway and is p53-independent. Cell Death Dis 2012; 3:e358; PMID:22833097; http://dx.doi.org/10.1038/cddis.2012.97
64. Gatta R, Dolfini D, Mantovani R. NF-Y joins E2Fs, p53 and other stress transcription factors at the apoptosis table. Cell Death Dis 2011; 2:e162; PMID:21614092; http://dx.doi.org/10.1038/cddis.2011.45
65. di Pietro A, Koster R, Boersma-van Eck W, Dam WA, Mulder NH, Gietema JA, de Vries EG, de Jong S. Proand anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cell Cycle 2012; 11:4552-62; PMID:23165211; http://dx.doi.org/10.4161/cc.22803
66. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A 2013; 110:3895-900; PMID:23431171; http://dx.doi.org/10.1073/pnas.1300490110
67. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog- like gerosuppression? Aging (Albany NY) 2012; 4:450-5; PMID:22869016
68. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159-65; PMID:22394614
69. Peche LY, Scolz M, Ladelfa MF, Monte M, Schneider C. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ 2012; 19:926-36; PMID:22117195; http://dx.doi.org/10.1038/cdd. 2011.173
70. Cho JH, Kim MJ, Kim KJ, Kim JR. POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) inhibits endothelial cell senescence through a p53 dependent pathway. Cell Death Differ 2012; 19:703-12; PMID:22052190; http://dx.doi.org/10.1038/cdd.2011.142
71. Chao SK, Horwitz SB, McDaid HM. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget 2011; 2:89-98; PMID:21399233
72. Donehower LA. Rapamycin as longevity enhancer and cancer preventative agent in the context of p53 deficiency. Aging (Albany NY) 2012; 4:660-1; PMID:23128359
73. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV, Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) 2012; 4:709-14; PMID:23123616
74. Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundström M, Micke P, Botling J, Soussi T. Data-driven unbiased curation of the Tp53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 2012; 109:9551-6; PMID:22628563; http://dx.doi.org/10.1073/pnas.1200019109
75. Jordan JJ, Menendez D, Sharav J, Beno I, Rosenthal K, Resnick MA, Haran TE. Low-level p53 expression changes transactivation rules and reveals superactivating sequences. Proc Natl Acad Sci U S A 2012; 109:14387-92; PMID:22908277; http://dx.doi.org/10.1073/pnas.1205971109
76. Bista M, Freund SM, Fersht AR. Domain-domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy. Proc Natl Acad Sci U S A 2012; 109:15752-6; PMID:22972749; http://dx.doi.org/10.1073/pnas. 1214176109
77. Wilcken R, Wang G, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci U S A 2012; 109:13584-9; PMID:22869713; http://dx.doi.org/10.1073/pnas.1211550109
78. Wang G, Fersht AR. First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci U S A 2012; 109:13590-5; PMID:22869710; http://dx.doi.org/10.1073/pnas.1211557109
79. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006; 22:741-53; PMID:16793544; http://dx.doi.org/10.1016/j.molcel.2006.05.015
80. Nagaich AK, Zhurkin VB, Durell SR, Jernigan RL, Appella E, Harrington RE. p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. Proc Natl Acad Sci U S A 1999; 96:1875-80; PMID:10051562; http://dx.doi.org/10.1073/pnas.96.5.1875
81. Melero R, Rajagopalan S, Lázaro M, Joerger AC, Brandt T, Veprintsev DB, Lasso G, Gil D, Scheres SH, Carazo JM, et al. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci U S A 2011; 108:557-62; PMID:21178074; http://dx.doi.org/10.1073/pnas.1015520107
82. Huang F, Rajagopalan S, Settanni G, Marsh RJ, Armoogum DA, Nicolaou N, Bain AJ, Lerner E, Haas E, Ying L, et al. Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A 2009; 106:20758-63; PMID:19933326; http://dx.doi.org/10. 1073/pnas.0909644106
83. Aramayo R, Sherman MB, Brownless K, Lurz R, Okorokov AL, Orlova EV. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res 2011; 39:8960-71; PMID:21764777; http://dx.doi.org/10.1093/nar/gkr386
84. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, Milner J, Orlova EV. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J 2006; 25:5191-200; PMID:17053786; http://dx.doi.org/10.1038/sj.emboj.7601382
85. Cherny DI, Brázdova M, Palecek J, Palecek E, Jovin TM. Sequestering of p53 into DNA-protein filaments revealed by electron microscopy. Biophys Chem 2005; 114:261-71; PMID:15829361; http://dx.doi.org/10.1016/j.bpc. 2004.12.042
86. Pham N, Lucumi A, Cheung N, Viadiu H. The tetramer of p53 in the absence of DNA forms a relaxed quaternary state. Biochemistry 2012; 51:8053-5; PMID:23025236; http://dx.doi.org/10.1021/bi301193k
87. Feng H, Jenkins LMM, Durell SR, Hayashi R, Mazur SJ, Cherry S, Tropea JE, Miller M, Wlodawer A, Appella E, et al. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure 2009; 17:202-10; PMID:19217391; http://dx.doi.org/10.1016/j.str.2008.12.009
88. Rowell JP, Simpson KL, Stott K, Watson M, Thomas JO. HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail. Structure 2012; 20:2014-24; PMID:23063560; http://dx.doi.org/10.1016/j.str.2012.09.004
89. Bochkareva E, Kaustov L, Ayed A, Yi GS, Lu Y, Pineda-Lucena A, Liao JC, Okorokov AL, Milner J, Arrowsmith CH, et al. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A 2005; 102:15412-7; PMID:16234232; http://dx.doi.org/10.1073/pnas. 0504614102
90. Cho YJ, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55; PMID:8023157; http://dx.doi.org/10.1126/science.8023157
91. Jeffery PD, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995; 267:1498-502; PMID:7878469; http://dx.doi.org/10.1126/science.7878469
92. Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996; 274:1001-5; PMID:8875926; http://dx.doi.org/10.1126/science.274.5289.1001
93. Cañadillas JMP, Tidow H, Freund SMV, Rutherford TJ, Ang HC, Fersht AR. Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A 2006; 103:2109-14; PMID:16461916; http://dx.doi.org/ 10.1073/pnas.0510941103
94. Clore GM, Ernst J, Omichinski JG, Kennedy WM, Sakaguchi K, Apella E, Gronenborn AM. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 1995; 2:321-33; PMID:7796267
95. Tidow H, Melero R, Mylonas E, Freund SM, Grossmann JG, Carazo JM, Svergun DI, Valle M, Fersht AR. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 2007; 104:12324-9; PMID:17620598; http://dx.doi.org/10.1073/pnas.0705069104
96. Lu Q, Tan Y-H, Luo R. Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B 2007; 111:11538-45; PMID:17824689; http://dx.doi.org/10. 1021/jp0742261
97. Barakat K, Issack BB, Stepanova M, Tuszynski J. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. PLoS One 2011; 6:e27651; PMID:22110706; http://dx.doi.org/10.1371/journal.pone.0027651
98. Santini S, Bizzarri AR, Cannistraro S. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin. J Mol Recognit 2011; 24:1043-55; PMID:22038811; http://dx.doi.org/10.1002/jmr.1153
99. Madhumalar A, Smith DJ, Verma C. Stability of the core domain of p53: insights from computer simulations. BMC Bioinformatics 2008; 9(Suppl 1):S17; PMID:18315848; http://dx.doi.org/10.1186/1471-2105-9-S1-S17
100. John K, Alla V, Meier C, Pützer BM. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ 2011; 18:874-86; PMID:21127500; http://dx.doi.org/10.1038/cdd.2010.153
101. Wassman CD, Baronio R, Demir O, Wallentine BD, Chen C-K, Hall LV, Salehi F, Lin DW, Chung BP, Hatfield GW, et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 2013; 4:1407; PMID:23360998; http://dx.doi.org/10.1038/ncomms2361
102. Demir O, Baronio R, Salehi F, Wassman CD, Hall L, Hatfield GW, Chamberlin R, Kaiser P, Lathrop RH, Amaro RE. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput Biol 2011; 7:e1002238; PMID:22028641; http://dx.doi.org/10.1371/journal.pcbi. 1002238
103. Yang Y, Tarapore RS, Jarmel MH, Tetreault M-P, Katz JP. p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation. Cell Cycle 2012; 11:4033-9; PMID:22990386; http://dx.doi.org/10. 4161/cc.22265
104. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2011; 2:e243; PMID:22170099; http://dx.doi.org/10.1038/ cddis.2011.129
105. Espinoza-Fonseca LM, Trujillo-Ferrara JG. Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. Biochem Biophys Res Commun 2006; 343:110-6; PMID:16530164; http://dx.doi.org/10.1016/j.bbrc.2006.02.129
106. Huang Y, Liu Z. Anchoring Intrinsically Disordered Proteins to Multiple Targets: Lessons from N-Terminus of the p53 Protein. Int J Mol Sci 2011; 12:1410-30; PMID:21541066; http://dx.doi.org/10.3390/ijms12021410
107. Mavinahalli JN, Madhumalar A, Beuerman RW, Lane DP, Verma C. Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics 2010; 11(Suppl 1):S5; PMID:20158876; http://dx.doi.org/10.1186/1471- 2164-11-S1-S5
108. Macchiarulo A, Giacchè N, Carotti A, Baroni M, Cruciani G, Pellicciari R. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model 2008; 48:1999-2009; PMID:18826207; http://dx.doi.org/10.1021/ci800146m
109. Allen WJ, Capelluto DGS, Finkielstein CV, Bevan DR. Modeling the relationship between the p53 C-terminal domain and its binding partners using molecular dynamics. J Phys Chem B 2010; 114:13201-13; PMID:20873738; http://dx.doi.org/10.1021/jp1011445
110. Gordo S, Martos V, Santos E, Menéndez M, Bo C, Giralt E, de Mendoza J. Stability and structural recovery of the tetramerization domain of p53- R337H mutant induced by a designed templating ligand. Proc Natl Acad Sci U S A 2008; 105:16426-31; PMID:18940924; http://dx.doi.org/10.1073/pnas.0805658105
111. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-53; PMID:8875929; http://dx.doi.org/10.1126/science.274.5289.948
112. Pan Y, Nussinov R. Lysine120 interactions with p53 response elements can allosterically direct p53 organization. PLoS Comput Biol 2010; 6; PMID:20700496; http://dx.doi.org/10.1371/journal.pcbi.1000878
113. VanAalten DMF, DeGroot BL, Findlay JBC, Berendsen HJC, Amadei A. A comparison of techniques for calculating protein essential dynamics. J Comput Chem 1997; 18:169-81; http://dx.doi.org/10.1002/(SICI)1096-987X(19970130)18:23. 0.CO;2-T
114. Levine AJ. The paths to death and differentiation. Cell Death Differ 2011; 18:1391-2; PMID:21841805; http://dx.doi.org/10.1038/cdd.2011.41
115. Levine AJ. The evolution of the p53 family of genes. Cell Cycle 2012; 11:214-5; PMID:22214668; http://dx.doi.org/10.4161/cc.11.2.18899
116. Rutkowski R, Gartner A. The shark in us: learning about the evolution of the p53 regulatory circuit. Cell Cycle 2012; 11:216-7; PMID:22214666; http://dx.doi.org/10.4161/cc.11.2.18901
117. Conforti F, Sayan AE, Sreekumar R, Sayan BS. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012; 3:e285; PMID:22419114; http://dx.doi.org/10.1038/cddis.2012.27
118. Grespi F, Amelio I, Tucci P, Annicchiarico- Petruzzelli M, Melino G. Tissue-specific expression of p73 C-terminal isoforms in mice. Cell Cycle 2012; 11:4474-83; PMID:23159862; http://dx.doi.org/10.4161/cc.22787
119. Masse I, Barbollat-Boutrand L, Molina M, Berthier- Vergnes O, Joly-Tonetti N, Martin MT, de Fromentel CC, Kanitakis J, Lamartine J. Functional interplay between p63 and p53 controls RUNX1 function in the transition from proliferation to differentiation in human keratinocytes. Cell Death Dis 2012; 3:e318; PMID:22673192; http://dx.doi.org/10.1038/cddis.2012.62
120. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2011; 2:1203-17; PMID:22203497
121. Ou HD, Löhr F, Vogel V, Mäntele W, Dötsch V. Structural evolution of C-terminal domains in the p53 family. EMBO J 2007; 26:3463-73; PMID:17581633; http://dx.doi.org/10.1038/sj.emboj.7601764
122. Belyi VA, Levine AJ. One billion years of p53/p63/p73 evolution. Proc Natl Acad Sci U S A 2009; 106:17609-10; PMID:19826090; http://dx.doi.org/10. 1073/pnas.0910634106
123. Lu F, Li YQ, Aubert I, Wong CS. Endothelial cells regulate p53-dependent apoptosis of neural progenitors after irradiation. Cell Death Dis 2012; 3:e324; PMID:22717579; http://dx.doi.org/10.1038/cddis.2012.59
124. Italiano D, Lena AM, Melino G, Candi E. Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle 2012; 11:4589-96; PMID:23187810; http://dx.doi.org/10.4161/cc.22853
125. Martynova E, Pozzi S, Basile V, Dolfini D, Zambelli F, Imbriano C, Pavesi G, Mantovani R. Gain-offunction p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 2012; 3:132-43; PMID:22361592
126. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011; 2:948-57; PMID:22248668
127. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18:1815-24; PMID:21941372; http://dx.doi.org/10.1038/cdd.2011.120
128. Shlevkov E, Morata G. A dp53/JNK-dependant feedback amplification loop is essential for the apoptotic response to stress in Drosophila. Cell Death Differ 2012; 19:451-60; PMID:21886179; http://dx.doi.org/10.1038/cdd.2011.113
129. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012; 11:4579-88; PMID:23187804; http://dx.doi.org/10.4161/cc.22852
130. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008; 22:2677-91; PMID:18805989; http://dx.doi.org/10.1101/gad.1695308
131. Agostini M, Tucci P, Killick R, Candi E, Sayan BS. Cervo PRdV, et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proceedings of the National Academy of Sciences of the United States of America 2011; 108:21093-8.
132. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, et al. microRNA-34a
133. Rufini A, Niklison-Chirou MV, Inoue S, Tomasini R, Harris IS, Marino A, Federici M, Dinsdale D, Knight RA, Melino G, et al. TAp73 depletion accelerates aging through metabolic dysregulation. Genes Dev 2012; 26:2009-14; PMID:22987635; http://dx.doi.org/10.1101/gad.197640.112
134. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, Melino G, Aberdam D. DNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 2011; 18:887-96; PMID:21127502; http://dx.doi.org/10.1038/cdd.2010.159
135. Marcel V, Petit I, Murray-Zmijewski F, Goullet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC. Diverse p63 and p73 isoforms regulate D133p53 expression through modulation of the internal Tp53 promoter activity. Cell Death Differ 2012; 19:816-26; PMID:22075982; http://dx.doi.org/ 10.1038/cdd.2011.152
136. Leonard MK, Kommagani R, Payal V, Mayo LD, Shamma HN, Kadakia MP. DNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization. Cell Death Differ 2011; 18:1924-33; PMID:21637289; http://dx.doi.org/10.1038/cdd.2011.73
137. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle 2012; 11:3638-48; PMID:22935697; http://dx.doi.org/10.4161/cc.21918
138. Salah Z, Bar-mag T, Kohn Y, Pichiorri F, Palumbo T, Melino G, Aqeilan RI. Tumor suppressor WWOX binds to DNp63α and sensitizes cancer cells to chemotherapy. Cell Death Dis 2013; 4:e480; PMID:23370280; http://dx.doi.org/10. 1038/cddis.2013.6
139. Nayak G, Cooper GM. p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling. Cell Death Dis 2012; 3:e400; PMID:23059819; http://dx.doi.org/10.1038/cddis.2012.138
140. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan BS, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 2012; 109:15312-7; PMID:22949650; http://dx.doi.org/10.1073/pnas.1110977109
141. Rivetti di Val Cervo P, Lena AM, Nicoloso M, Rossi S, Mancini M, Zhou H, Saintigny G, Dellambra E, Odorisio T, Mahé C, et al. p63-microRNA feedback in keratinocyte senescence. Proc Natl Acad Sci U S A 2012; 109:1133-8; PMID:22228303; http://dx.doi.org/10.1073/pnas.1112257109
142. Amelio I, Grespi F, Annicchiarico-Petruzzelli M, Melino G. p63 the guardian of human reproduction. Cell Cycle 2012; 11:4545-51; PMID:23165243; http://dx.doi.org/10.4161/cc.22819
143. Paris M, Rouleau M, Pucéat M, Aberdam D. Regulation of skin aging and heart development by TAp63. Cell Death Differ 2012; 19:186-93; PMID:22158419; http://dx.doi.org/10.1038/cdd.2011.181
144. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNF alpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012; 3
145. Yasuda T, Oda S, Li Z, Kimori Y, Kamei Y, Ishikawa T, Todo T, Mitani H. Gamma-ray irradiation promotes premature meiosis of spontaneously differentiating testis-ova in the testis of p53-deficient medaka (Oryzias latipes). Cell Death Dis 2012; 3:e395; PMID:23034330; http://dx.doi.org/10.1038/ cddis.2012.133
146. Markert EK, Levine AJ, Vazquez A. Proliferation and tissue remodeling in cancer: the hallmarks revisited. Cell Death Dis 2012; 3:e397; PMID:23034332; http://dx.doi.org/10.1038/cddis.2012.140
147. de Bie P, Ciechanover A. Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ 2011; 18:1393-402; PMID:21372847; http://dx.doi.org/10.1038/cdd.2011.16
148. Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr HW, Rödel F, et al. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis 2012; 3:e294; PMID:22476102; http://dx.doi.org/10.1038/cddis.2012.35
149. Burns DM, D'Ambrogio A, Nottrott S, Richter JD. CPEB and two poly(A) polymerases control miR- 122 stability and p53 mRNA translation. Nature 2011; 473:105-8; PMID:21478871; http://dx.doi.org/10.1038/nature09908
150. Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, et al. Mdm2 controls CREBdependent transactivation and initiation of adipocyte differentiation. Cell Death Differ 2012; 19:1381-9; PMID:22388350; http://dx.doi.org/10.1038/cdd.2012.15
151. Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2011; 2:234-8; PMID:21406728
152. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2011; 2:e148; PMID:21509038; http://dx.doi.org/10.1038/cddis. 2011.33
153. Davies L, Spiller D, White MRH, Grierson I, Paraoan L. PERP expression stabilizes active p53 via modulation of p53-MDM2 interaction in uveal melanoma cells. Cell Death Dis 2011; 2:e136; PMID:21451571; http://dx.doi.org/10.1038/ cddis.2011.19
154. Zhang L, Huang N-J, Chen C, Tang W, Kornbluth S. Ubiquitylation of p53 by the APC/C inhibitor Trim39. Proc Natl Acad Sci U S A 2012; 109:20931-6; PMID:23213260; http://dx.doi.org/10.1073/pnas.1212047110
155. Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, et al. Activation of the p53 pathway by smallmolecule- induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A 2012; 109:11788-93; PMID:22745160; http://dx.doi.org/10.1073/pnas.1203789109
156. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis 2011; 2:e156; PMID:21562588; http://dx.doi.org/10.1038/cddis.2011.39
157. de Lange J, Verlaan-de Vries M, Teunisse AFAS, Jochemsen AG. Chk2 mediates RITA-induced apoptosis. Cell Death Differ 2012; 19:980-9; PMID:22158418; http://dx.doi.org/10.1038/cdd.2011.182
158. Bursać S, Brdovćak MC, Pfannkuchen M, OrsolićvI, Golomb L, Zhu Y, Katz C, Daftuar L, Grabušić K, Vukelić I, et al. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proc Natl Acad Sci U S A 2012; 109:20467-72; PMID:23169665; http://dx.doi.org/10.1073/pnas. 1218535109
159. Joerger AC, Rajagopalan S, Natan E, Veprintsev DB, Robinson CV, Fersht AR. Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A 2009; 106:17705-10; PMID:19815500; http://dx.doi.org/10.1073/pnas.0905867106
160. Ethayathulla AS, Tse P-W, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H. Structure of p73 DNAbinding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci U S A 2012; 109:6066-71; PMID:22474346; http://dx.doi.org/10.1073/ pnas.1115463109
161. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137:87-98; PMID:19345189; http://dx.doi.org/10.1016/j.cell.2009.01.039
162. Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139:1327-41; PMID:20064378; http://dx.doi.org/10.1016/j.cell.2009.11.026
163. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 2010; 5:725-38; PMID:20360767; http://dx.doi.org/10.1038/nprot.2010.5
164. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577-90; PMID:12667443; http://dx.doi.org/10.1016/S1097-2765(03)00050-9
165. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, et al. GROMACS 4.5: a highthroughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013; 29:845-54; PMID:23407358; http://dx.doi.org/10.1093/ bioinformatics/btt055
166. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw DE. Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 2010; 78:1950-8; PMID:20408171
167. Jorgensen W, Chandrasekhar J, Madura J, Impey R, Klein M. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983:79
168. Darden T, York D, Pedersen L. Particle Mesh Ewald - an N log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98:10089-92; http://dx.doi.org/10.1063/1.464397
169. Hess B, Bekker H, Berendsen HJC, Fraaije J. LINCS: A linear constraint solver for molecular simulations. J Comput Chem 1997; 18:1463-72; http://dx.doi.org/10.1002/(SICI)1096-987X(199709)18:12 3.0.CO;2-H
170. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A 2001; 98:10037-41; PMID:11517324; http://dx.doi.org/10.1073/pnas.181342398
171. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-8, 27-8; PMID:8744570; http://dx.doi.org/10.1016/0263-7855(96) 00018-5